Ash Cooper
Life in the old dog yet: how biotech firms are looking to extend the lives of our pets
In a development that raises hopes as well as ethical questions, several biotech startups are racing to create treatments aimed at extending the healthy lifespan—often called “healthspan”—of pets. Driven by robust venture capital funding, these companies are investigating everything from hormone-suppressing tablets to targeted gene therapies that promise to stave off age-related diseases in cats and dogs.
· 5 min read
